RxDoctor Payments Data

Gavin Triche, PA

Physician Assistant · Gray, LANPI 1265985915

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.8% of the total across 424 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,806 and has fallen 78.8% since, to $595 in 2025. Among physician assistant clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,557in general payments, 2019–2025

Across 424 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$715
  • Amgen$566
  • Sanofi$410
  • Lilly USA, LLC$387
  • UCB, Inc.$344
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$7,46299%
  • Education$941%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,557 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.

See all physician assistant providers in Louisiana

Medicare billing

Part B allowed, 2024
$37,483
Medicare patients
177
Services billed
1,718

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe61$51,992
UbrelvyUbrogepant13$22,542
Emgality PenGalcanezumab-Gnlm13$10,326
Carbamazepine ErCarbamazepine22$3,287
Memantine Hcl164$2,802
Entacapone11$1,953
Lamotrigine37$1,208
Phenytoin Sodium Extended18$865
Zonisamide28$790
Levetiracetam34$590
Propranolol Hcl24$321
Donepezil Hcl45$313
Primidone15$280
RizatriptanRizatriptan Benzoate20$237
Carbidopa-LevodopaCarbidopa/Levodopa26$200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$1,566$22,54213 claims
Upsher-smith Laboratories LLCTopiramate$45$13323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.

Other physician assistant in Gray

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →